Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The EMA's CHMP recommended approval of daraxonrasib for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

VS-7375 produced a responses previously treated metastatic pancreatic ductal adenocarcinoma.

The resubmission follows a third complete response letter issued in July 2026 that cited manufacturing deficiencies rather than efficacy or safety concerns.

The FDA granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.

A planned interim analysis of the radiopharmaceutical RYZ101 showed improved PFS by blinded independent central review vs standard of care.

The top 5 OncLive TV videos of the week.

Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.